Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.

quaterly report

14.05.2007

IC31TM - Clinical results emphasize broad and commercial use in 
vaccine development

» Protective profile for IC31TM in Phase I Tuberculosis vaccine trial
- strong   T-cell immune responses in humans confirming broad 
pre-clinical data base » Promising pre-clinical data for the use of 
IC31TM in next generation Flu   vaccines - first clinical trials 
planned for 2007 » Next Milestones - start of a Phase I 
"proof-of-concept" clinical trial for   an IC31TM adjuvanted Flu 
vaccine and strong focus on a commercial use of   IC31TM and further 
strategic partnerships

All development projects on track and within expected timelines

» Japanese Encephalitis vaccine - all preparations for expected 
market launch   in the US early 2008 and late 2008 in Europe are on 
track   Regulatory clearance to start a pediatric Phase II clinical 
trial in India   obtained - start of Phase II trial within the next 
few weeks » Hepatitis C vaccine - Phase II "proof-of-concept" study 
fully recruited -   first data expected by mid 2007 - forward 
strategies comprise options for   mono- and/or combination therapies 
» Pneumococcus vaccine - preparations for start of Phase I clinical 
trial on   track

Nosocomial (hospital-acquired) infections - Building the leading 
vaccine franchise

» Staphylococcus aureus vaccine partnered with Merck & Co. - safe and
immunogenic in Phase I clinical trials - Phase II expected to start 
in 2007 » Pseudomonas vaccine - preparations for start of clinical 
Phase II/III trials   on track » Enterococcus/Klebsiella vaccines - 
AIP® accelerated to progress into   clinical development

Strong financial position - Net loss further reduced

» EUR 7.1 million net loss for Q1 2007 - down 19.3 percent as 
compared to Q1   2006 » Increase of aggregate revenues -  EUR 1.5 
million in Q1 2007 compared to   EUR 0.3 million in Q1 2006 » EUR 7.4
million R&D expenses in Q1 2007 - up 8.8 percent as compared to Q1   
2006 » Strong cash position with EUR 86.3 million in liquid funds at 
March 31, 2007

end of announcement                               euro adhoc 14.05.2007 06:57:42

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market